Home › Trial NCT04641754
A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
- Trial IDNCT04641754
- StatusUnknown
- PhasePhase 2
- Study typeInterventional
- SponsorQilu Pharmaceutical Co., Ltd.
- Enrollment176
- Start date2019-03-07
- ConditionsNon-small Cell Lung Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.